Form 8-K - Current report:
SEC Accession No. 0002036042-25-000014
Filing Date
2025-05-12
Accepted
2025-05-12 07:12:56
Documents
14
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sion-20250512.htm   iXBRL 8-K 26345
2 EX-99.1 sion1q25earningsrelease.htm EX-99.1 47226
  Complete submission text file 0002036042-25-000014.txt   210037

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sion-20250512.xsd EX-101.SCH 1822
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sion-20250512_lab.xml EX-101.LAB 22777
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sion-20250512_pre.xml EX-101.PRE 13073
16 EXTRACTED XBRL INSTANCE DOCUMENT sion-20250512_htm.xml XML 3127
Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Filer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42504 | Film No.: 25932571
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)